Abstract 4498
Background
Patients’ involvement in the health technology assessment (HTA) decision-making process is important for transparency, legitimacy and fairness. The study objectives were to understand breast cancer patients’ perspectives when choosing their treatment, highlight treatment characteristics valued as most important by patients and gain information on patients’ trade-offs between available treatments.
Methods
A discrete choice experiment survey of breast cancer patients was conducted in Spain, Poland, France and Ireland. The survey design included: literature review, qualitative research, cognitive debriefing, data collection and analysis. A panel of experts from participating countries (physicians, patient group representatives, ex-payers) selected the survey treatment attributes: progression-free survival (PFS), febrile neutropenia (FN), pain, functional well-being (FWB) and out-of-pocket payment (OPP). Patients selected (or opted-out) between two unlabelled hypothetical treatments containing the previously mentioned five attributes. Panels of breast cancer patients were recruited as respondents and the questionnaire was deployed through a website platform. A D-efficient experimental design with 16 choice-sets was constructed and a conditional logistic model was used to estimate patients’ preferences. Marginal rates of substitution (MRS) was used to estimate out-of-pocket payments.
Results
In total, 317 breast cancer patients completed the survey. FWB and pain were the most important attributes chosen by patients. Respondents were willing to pay €17,288 out-of-pocket to move from severe to no impairment in FWB, followed by moderate impairment (€15,297) and from severe pain to no pain state (€15,138). Patients would pay €574 annually for one additional PFS month. Preferences differed by age for FN and FWB; highly educated patients have stronger preference for PFS compared to non-highly educated.
Conclusions
Breast cancer treatments that improve pain, FWB and PFS are considered preferred treatments from patients’ perspective.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novartis Oncology Region Europe.
Funding
Novartis Oncology Region Europe.
Disclosure
T. Konstantopoulou: Full / Part-time employment: Novartis Oncology. E. Stamuli: Research grant / Funding (institution): Novartis Oncology Region Europe. D. Ross: Advisory / Consultancy: Novartis Oncology Region Europe. R. Pacheco: Full / Part-time employment: Novartis Oncology Region Europe.
Resources from the same session
2840 - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors
Presenter: Christina Dieli-Conwright
Session: Poster Display session 2
Resources:
Abstract
869 - Impact of Education for Breast self examination in Rural Indian Women on Early Detection - results of POC study
Presenter: Sneha Parchuri
Session: Poster Display session 2
Resources:
Abstract
1951 - Breast cancer incidence and survival in renal transplant patients: 35-year experience
Presenter: Michalis Kontos
Session: Poster Display session 2
Resources:
Abstract
2017 - The changing landscape of breast cancer incidence after treatment for Hodgkin’s disease
Presenter: Amelia Benjamin
Session: Poster Display session 2
Resources:
Abstract
1780 - Number of deliveries as a prognostic factor in different breast cancer subtypes
Presenter: Anniina Jääskeläinen
Session: Poster Display session 2
Resources:
Abstract
4650 - Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial
Presenter: Ana Joaquim
Session: Poster Display session 2
Resources:
Abstract
4962 - Study On the Socioeconomic and Clinical Factors Affecting the Proportion of Breast Conserving Surgery in Chinese Women Breast Cancer
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5451 - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?
Presenter: Marco Giavarra
Session: Poster Display session 2
Resources:
Abstract
888 - The value of genetic counselling in breast cancer genetic testing and clinical management
Presenter: Vicki Kiesel
Session: Poster Display session 2
Resources:
Abstract
4005 - Elderly patients in the Japanese Breast Cancer Registry
Presenter: Masataka Sawaki
Session: Poster Display session 2
Resources:
Abstract